Clinical Depression
Clinical depression (also called
major depressive disorder, or sometimes
unipolar when compared with
bipolar disorder) is a state of intense sadness, melancholia or despair that has advanced to the point of being disruptive
to an individual's social functioning and/or activities of daily living. Although a low mood or state of dejection that
does not affect functioning is often colloquially referred to as depression, clinical depression is a clinical diagnosis
and may be different from the everyday meaning of "being depressed." Many people identify the feeling of being depressed
as "feeling sad for no reason", or "having no motivation to do anything." One suffering from depression may feel tired,
sad, irritable, lazy, unmotivated, and apathetic. Clinical depression is generally acknowledged to be more serious than
normal depressed feelings. It often leads to constant negative thinking and sometimes substance abuse.
Without careful assessment, delirium can easily be confused with depression and a number of other psychiatric disorders
because many of the signs and symptoms are conditions present in depression, as well as other mental illnesses including
dementia and psychosis.
Current Research
For current research articles click
- here
History
The modern idea of depression appears similar to the much older concept of melancholia. The name melancholia derives
from "black bile," one of the "four humours" postulated by Galen.
Clinical depression was originally considered to be a chemical imbalance in transmitters in the brain, a theory based
on observations made in the 1950s of the effects of reserpine and isoniazid in altering monoamine neurotransmitter
levels and affecting depressive symptoms. Since these suggestions, many other causes for clinical depression have
been proposed.
Prevalence
Clinical depression affects about 16% of the population on at least one occasion in their lives. In some countries,
such as Australia, one in four women and one in six men will suffer from depression. The mean age of onset, from a
number of studies, is in the late 20s. About twice as many females as males report or receive treatment for clinical
depression, though this imbalance is shrinking over the course of recent history; this difference seems to completely
disappear after the age of 50–55. Clinical depression is currently the leading cause of disability in North America
as well as other countries, and is expected to become the second leading cause of disability worldwide (after heart
disease) by the year 2020, according to the World Health Organization.
Symptoms
According to the DSM-IV-TR criteria for diagnosing a major depressive disorder (cautionary statement) one of the
following two elements must be present for a period of at least two weeks:
- Depressed mood, or
- Anhedonia
It is sufficient to have either of these symptoms in conjunction with five of a list of other symptoms over a two-week
period. These include:
- Feelings of overwhelming sadness and/or fear, or the seeming inability to feel emotion (emptiness).
- A decrease in the amount of interest or pleasure in all, or almost all, daily activities.
- Changing appetite and marked weight gain or loss.
- Disturbed sleep patterns, such as insomnia, loss of REM sleep, or excessive sleep (Hypersomnia).
- Psychomotor agitation or retardation nearly every day.
- Fatigue, mental or physical, also loss of energy.
- Intense feelings of guilt, nervousness, helplessness, hopelessness, worthlessness, isolation/loneliness
and/or anxiety.
- Trouble concentrating, keeping focus or making decisions or a generalized slowing and obtunding of
cognition, including memory.
- Recurrent thoughts of death (not just fear of dying), desire to just "lie down and die" or "stop
breathing", recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific
plan for committing suicide.
- Feeling and/or fear of being abandoned by those close to one.
Other symptoms often reported but not usually taken into account in diagnosis include:
- Self-loathing.
- A decrease in self-esteem.
- Inattention to personal hygiene.
- Sensitivity to noise.
- Physical aches and pains, and the belief these may be signs of serious illness.
- Fear of 'going mad'.
- Change in perception of time.
- Periods of sobbing.
- Possible behavioral changes, such as aggression and/or irritability.
Depression in children is not as obvious as it is in adults. Here are some symptoms that children might display:
- Loss of appetite.
- Irritability.
- Sleep problems, such as recurrent nightmares.
- Learning or memory problems where none existed before.
- Significant behavioral changes; such as withdrawal, social isolation, and aggression.
An additional indicator could be the excessive use of drugs or alcohol. Depressed adolescents are at particular risk
of further destructive behaviours, such as eating disorders and self-harm.
One of the most widely used instruments for measuring depression severity is the Beck Depression Inventory, a
21-question multiple choice survey.
It is hard for people who have not experienced clinical depression, either personally or by regular exposure to
people suffering it, to understand its emotional impact and severity, interpreting it instead as being similar to
"having the blues" or "feeling down." As the list of symptoms above indicates, clinical depression is a serious,
potentially lethal systemic disorder characterized by the psychiatric profession as interlocking physical, affective,
and cognitive symptoms that have consequences for function and survival well beyond sad or painful feelings.
Mnemonics
Mnemonics commonly used to remember the DSM-IV criteria are
SIGECAPS (
sleep,
interest (anhedonia),
guilt,
energy,
concentration,
appetite,
psychomotor,
suicidality) and
DEAD SWAMP (
depressed mood,
energy,
anhedonia,
death
(thoughts of),
sleep,
worthlessness/guilt,
appetite,
mentation,
psychomotor).
Types of Depression
The diagnostic category major depressive disorder appears in the Diagnostic and Statistical Manual of Mental Disorders
of the American Psychiatric Association. The term is generally not used in countries which instead use the ICD-10
system, but the diagnosis of depressive episode is very similar to an episode of major depression. Clinical depression
also usually refers to acute or chronic depression severe enough to need treatment. Minor depression is a less-used
term for a subclinical depression that does not meet criteria for major depression but where there are at least two
symptoms present for two weeks.
Major Clinical Depression
Major Depression, or, more properly,
Major Depressive Disorder (MDD), is characterized by a severely depressed
that persists for at least two weeks. Major Depressive Disorder is specified as either "a single episode" or "recurrent";
periods of depression may occur as discrete events or as recurrent over the lifespan. Episodes of major or clinical
depression may be further divided into mild, major or severe. Where the patient has already had an episode of mania
or markedly elevated mood, a diagnosis of
bipolar disorder (also called bipolar affective disorder) is usually made
instead of MDD; depression without periods of elation or mania is therefore sometimes referred to as unipolar depression
because their mood remains on one pole. The diagnosis also usually excludes cases where the symptoms are a normal result
of bereavement.
Diagnosticians recognize several possible subtypes of Major Depressive Disorder. ICD-10 does not specify a melancholic
subtype, but does distinguish on presence or absence of psychosis.
- Depression with Melancholic Features - Melancholia is characterized by a loss of pleasure (anhedonia) in
most or all activities, a failure of reactivity to pleasurable stimuli, a quality of depressed mood more
pronounced than that of grief or loss, a worsening of symptoms in the morning hours, early morning waking,
psychomotor retardation, anorexia (excessive weight loss, not to be confused with Anorexia Nervosa), or
excessive guilt.
- Depression with Atypical Features - Atypical Depression is characterized by mood reactivity (paradoxical
anhedonia) and positivity, significant weight gain or increased appetite, excessive sleep or somnolence
(hypersomnia), leaden paralysis, or significant social impairment as a consequence of hypersensitivity
to perceived interpersonal rejection. Contrary to its name, atypical depression is the most common form
of depression.
- Depression with Psychotic Features - Some people with Major Depressive or Manic episode may experience
psychotic features. They may be presented with hallucinations or delusions that are either mood-congruent
(content coincident with depressive themes) or non-mood-congruent (content not coincident with depressive
themes). It is clinically more common to encounter a delusional system as an adjunct to depression than
to encounter hallucinations, whether visual or auditory.
Other Categories of Depression
Dysthymia is a long-term, mild depression that lasts for a minimum of two years. There must be persistent depressed
mood continuously for at least two years. By definition the symptoms are not as severe as with Major Depression, although
those with Dysthymia are vulnerable to co-occurring episodes of Major Depression. This disorder often begins in adolescence
and crosses the lifespan. People who are diagnosed with major depressive episodes and dysthymic disorder are diagnosed
with double depression. Dysthymic disorder develops first and then one or more major depressive episodes happen later.
Bipolar I Disorder is an episodic illness in which moods may cycle between mania and depression. In the United States,
Bipolar Disorder was previously called Manic Depression. This term is no longer favored by the medical community, however,
even though depression plays a much stronger (in terms of disability and potential for suicide) role in the disorder.
"Manic Depression" is still often used in the non-medical community. Bipolar II Disorder is an episodic illness that is
defined primarily by depression but evidences episodes of hypomania.
Postpartum Depression or Post-Natal Depression is clinical depression that occurs within two years of childbirth. Owing
to physical, mental and emotional exhaustion combined with sleep-deprivation, motherhood can "set women up", so to speak,
for clinical depression.
Premenstrual dysphoriais is a pattern of recurrent depressive symptoms tied to the menstrual cycle. The premenstrual
decline in brain serotonin function is strongly correlated with the concomitant worsening of self-rated cardinal mood
symptoms. Of considerable clinical importance, the recent understanding of premenstrual dysphoria as depression
points directly to effective treatment with Selective serotonin reuptake inhibitor (SSRI) antidepressants. Previously,
disrupting ovarian cyclicity had been the only recognized treatment. A recent review of studies of a number of SSRIs has
revealed that they can effectively ameliorate symptoms of premenstrual dysphoria and may actually work best when taken
only during the part of the menstrual cycle when dysphoric symptoms are evident.
The Role of Anxiety in Depression
Anxiety
The different types of Depression and
Anxiety are classified separately by the DSM-IV-TR, with the exception of
hypomania, which is included in the
bipolar disorder category. Despite the different categories, depression and
anxiety
can indeed be co-occurring (occurring together, independently, and without mood congruence), or comorbid (occurring
together, with overlapping symptoms, and with mood congruence). In an effort to bridge the gap between the DSM-IV-TR
categories and what clinicians actually encounter, experts such as Herman Van Praag of Maastricht University have
proposed ideas such as
anxiety/aggression-driven depression. This idea refers to an
anxiety/depression spectrum for
these two disorders, which differs from the mainstream perspective of discrete diagnostic categories.
Although there is no specific diagnostic category for the comorbidity of depression and
anxiety in the DSM or ICD,
the National Comorbidity Survey (US) reports that 58 percent of those with major depression also suffer from lifetime
anxiety. Supporting this finding, two widely accepted clinical colloquialisms include:
- agitated depression - a state of depression that presents as anxiety and includes akathisia, suicide,
insomnia (not early morning wakefulness), nonclinical (meaning "doesn't meet the standard for formal
diagnosis") and nonspecific panic, and a general sense of dread.
- akathitic depression - a state of depression that presents as anxiety or suicidality and includes
akathisia but does not include symptoms of panic.
It is also clear that even mild
anxiety symptoms can have a major impact on the course of a depressive illness, and
the commingling of any anxiety symptoms with the primary depression is important to consider. A pilot study by Ellen
Frank et al., at the University of Pittsburgh, found that depressed or
bipolar patients with lifetime panic symptoms
experienced significant delays in their remission. These patients also had higher levels of residual impairment, or
the ability to get back into the swing of things. On a similar note, Robert Sapolsky of Stanford University and others
also argue that the relationship between stress,
anxiety, and depression could be measured and demonstrated
biologically. To that point, a study by Heim and Nemeroff et al., of Emory University, found that depressed and
anxious women with a history of childhood abuse recorded higher heart rates and the stress hormone ACTH when
subjected to stressful situations.
Hypomania
Hypomania, as the name suggests, is a state of mind or behavior that is "below" (hypo) mania. In other words, a person
in a hypomanic state often displays behavior that has all the hallmarks of a full-blown mania (e.g., marked elevation
of mood that is characterized by euphoria, over activity, disinhibition, impulsivity, a decreased need for sleep,
hypersexuality), but these symptoms, though disruptive and seemingly out of character, are not so pronounced as to
be considered a diagnosably manic episode. In a psychiatric context, it is important to identify the possible presence
and characteristics of manic and hypomanic episodes, since these may lead to a diagnosis of
bipolar disorder, which is
medically treated differently from depression.
Another important point is that hypomania is a diagnostic category that includes both
anxiety and depression. It often
presents as a state of
anxiety that occurs in the context of a clinical depression. Patients in a hypomanic state often
describe a sense of extreme generalized or specific
anxiety, recurring panic attacks,
night terrors, guilt, and agency
(as it pertains to codependence and counterdependence). All of this happens while they are in a state of retarded or
somnolent depression. This is the type of depression in which a person is lethargic and unable to move through life.
The terms retarded and somnolent are shorthand for states of depression that include lethargy, hypersomnia, a lack of
motivation, a collapse of ADLs (activities of daily living), and social withdrawal. This is similar to the shorthand
used to describe an "agitated" or "akathitic" depression.
In considering the hypomania-depression connection, a distinction should be made between
anxiety, panic, and stress.
Anxiety is a physiological state that is caused by the sympathetic nervous system.
Anxiety does not need an outside
influence to occur. Panic is related to the "fight or flight" mechanism. It is a reaction, induced by an outside
stimulus, and is a product of the sympathetic nervous system and the cerebral cortex. More plainly, panic is an
anxiety state that we are thinking about. Finally, stress is a psychosocial reaction, influenced by how a person
filters nonthreatening external events. This filtering is based on one's own ideas, assumptions, and expectations.
Taken together, these ideas, assumptions, and expectations are called social constructionism.
On a final note, researchers at the University of California, San Diego, under the guidance of Hagop Akiskal MD,
have found convincing evidence for the co-occurrence of hypomanic symptoms associated with a diagnosis of depression
where the diagnosis does not meet criteria for
Bipolar Disorder. Symptoms under consideration, such
as irritability, misdirected anger, and compulsivity, also may not present sufficiently to be considered a hypomanic
episode, as described by a Bipolar II Disorder. As noted in the Frank study mentioned above, this particular course of
the disease, with the breakthrough of
anxiety, may have a significant impact on the overall course of the depression.
This idea of co-occurring
anxiety and depression is supported in a study by Giovanni Cassano MD of the University of
Pisa and his collaborators on the Spectrum Project, who found a correlation between lifetime hypomanic and manic symptoms
and the severity of the depression.
These authors, along with many other researchers, argue in support of a revision of the approach to psychiatric
diagnosis into what is being called the mood spectrum, so as to "(make) more accurate diagnostic evaluation(s)." This
approach, although controversial, has begun to be given consideration by many behavioral health professionals.
Causes of Depression
No specific cause for depression has been identified, but a number of factors are believed to be involved.
- Heredity – The tendency to develop depression may be inherited; there is some evidence that this disorder
may run in families, though biological and environmental factors may both be responsible. A 2004 press
release from the National Institute of Mental Health declares "major depression is thought to be 40–70
percent heritable, but likely involves an interaction of several genes with environmental events".
- Physiology – Many modern antidepressant drugs change levels of certain neurotransmitters, such as
serotonin and norepinephrine (noradrenaline). However, the relationship between serotonin, SSRIs, and
depression usually is typically greatly oversimplified when presented to the public, and is not supported
by the evidence, but may instead involve changes in neural plasticity. Recent research has suggested that
there may be a link between depression and neurogenesis of the hippocampus. This horseshoe-shaped
structure is a center for both mood and memory. Loss of neurons in the hippocampus is found in depression
and correlates with impaired memory and dysthemic mood. The hippocampus regains mass when exposed to
treatments that increase brain serotonin, and when regrown, mood and memory tend to be restored.
- Seasonal affective disorder - (SAD) is a type of depressive disorder that occurs in the winter when daylight
hours are short. It is believed that the body's production of melatonin, which is produced at higher
levels in the dark, plays a major part in the onset of SAD and that many sufferers respond well to
bright light therapy, also known as phototherapy.
- Psychological factors – Low self-esteem and self-defeating or distorted thinking are connected with
depression. Although it is not clear which is the cause and which is the effect, it is known that
depressed persons who are able to make corrections in their thinking patterns can show improved mood
and self-esteem. Psychological factors related to depression include the complex development of one's
personality and how one has learned to cope with external environmental factors such as stress.
- Early experiences – Events such as the death of a parent, abandonment or rejection, neglect, chronic
illness, and physical, psychological, or sexual abuse can also increase the likelihood of depression
later in life. Post-traumatic stress disorder (PTSD) includes depression as one of its major symptoms.
- Life experiences – Job loss, poverty, financial difficulties, gambling addiction, long periods of
unemployment, the loss of a spouse or other family member, rape, divorce or the end of a committed
relationship, involuntary celibacy, inability to have proper sex or premature ejaculation or other
traumatic events may trigger depression. Long-term stress at home, work, or school can also be involved.
Bullying in late adolescence is also thought to be a contributing factor.
- Medical conditions – Certain illnesses, including cardiovascular disease, hepatitis, mononucleosis,
hypothyroidism, and organic brain damage caused by degenerative conditions such as Parkinson's disease,
Multiple Sclerosis or by traumatic blunt force injury may contribute to depression, as may certain
prescription drugs such as hormonal contraception methods and steroids. Gender dysphoria can also cause
depression.
- Diet – The increase in depression in industrialised societies has been linked to diet, particularly to
reduced levels of omega-3 fatty acids in intensively farmed food and processed foods. This link has
been at least partly validated by studies using dietary supplements in schools and by a double-blind
test in a prison. An excess of omega-6 fatty acids in the diet was shown to cause depression in rats.
- Alcohol and other drugs – Alcohol can have a negative effect on mood, and misuse of alcohol,
benzodiazepine-based tranquilizers, and sleeping medications can all play a major role in the length
and severity of depression.
- Postpartum depression (also known as postnatal depression) – Dr. Ruta M Nonacs writes that while many women
experience some mood changes after giving birth, "10-15% of women experience a more disabling and
persistent form of mood disturbance (e.g., postpartum depression, postpartum psychosis)". When it
occurs, the onset typically is within three months after delivery, and it may last for several months.
About two new mothers out of a thousand experience the more serious depressive disorder Postnatal
Psychosis which includes hallucinations and/or delusions.
- Living with a depressed person – Those living with someone suffering from depression experience increased
anxiety and life disruption, increasing the possibility of also becoming depressed.
- Evolutionary biological hypotheses of depression – Evolutionary analyses usually consider possible functions
for depressed mood as well as clinical depression.
- The psychic pain hypothesis: psychic pain, such as depression, is analogous to physical pain.
The function of physical pain is to inform the organism that it is suffering damage, to motivate
it to withdraw from the source of damage, and to learn to avoid such damage-causing circumstances
in the future. Analogously, depression informs the sufferer that current circumstances, such as
the loss of a mate, are imposing a threat to biological fitness, it motivates the sufferer to
cease activities that led to the costly situation, if possible, and it causes him or her to
learn to avoid similar circumstances in the future. Proponents of this view tend to focus on
low mood, and regard clinical depression as a dysfunctional extreme of low mood. See, e.g.,
Nesse 2000 and Keller and Nesse 2005; see also Hagen and Barrett n.d.
- Rank theory: If an individual is involved in a lengthy fight for dominance in a social group and
is clearly losing, depression causes the individual to back down and accept the submissive role.
In doing so, the individual is protected from unnecessary harm. In this way, depression helps
maintain a social hierarchy. This theory is a special case of a more general theory derived from
the psychic pain hypothesis: that the cognitive response that produces modern-day depression
evolved as a mechanism that allows people to assess whether they are in pursuit of an unreachable
goal, and if they are, to motivate them to desist. See, e.g., Nesse 2000.
- Honest signaling theory: When social partners have conflicts of interest, 'cheap' signals of
need, such as crying, might not be believed. Biologists and economists have proposed that signals
with inherent costs can credibly signal information when there are conflicts of interest. The
symptoms of major depression, such as loss of interest in virtually all activities and suicidality,
are inherently costly, but, as costly signaling theory requires, the costs differ for individuals
in different states. For individuals who are not genuinely in need, the fitness cost of major
depression is very high because it threatens the flow of fitness benefits. For individuals who
are in genuine need, however, the fitness cost of major depression is low because the individual
is not generating many fitness benefits. Thus, only an individual in genuine need can afford to
suffer major depression. Major depression therefore serves as an honest, or credible, signal of
need. See, e.g., Hagen 2003, Watson and Andrews 2002.
- Social navigation or niche change theory: The social navigation, bargaining, or niche change
hypothesis suggests that depression, operationally defined as a combination of prolonged
anhedonia and psychomotor retardation or agitation, provides a focused sober perspective on
socially imposed constraints hindering a person’s pursuit of major fitness enhancing projects.
Simultaneously, publicly displayed symptoms, which reduce the depressive's ability to conduct
basic life activities, serve as a social signal of need; the signal's costliness for the
depressive certifies its honesty. Finally, for social partners who find it uneconomical to
respond helpfully to an honest signal of need, the same depressive symptoms also have the
potential to extort relevant concessions and compromises. Depression’s extortionary power comes
from the fact that it retards the flow of just those goods and services such partners have come
to expect from the depressive under status quo socioeconomic arrangements.
Thus depression may be a social adaptation especially useful in motivating a variety of social
partners, all at once, to help the depressive initiate major fitness-enhancing changes in their
socioeconomic life. There are extraordinarily diverse circumstances under which this may become
necessary in human social life, ranging from loss of rank or a key social ally which makes the
current social niche uneconomic to having a set of creative new ideas about how to make a
livelihood which begs for a new niche. The social navigation hypothesis emphasizes that an
individual can become tightly ensnared in an overly restrictive matrix of social exchange
contracts, and that this situation sometimes necessitates a radical contractual upheaval that
is beyond conventional methods of negotiation. Regarding the treatment of depression, this
hypothesis calls into question any assumptions by the clinician that the typical cause of
depression is related to maladaptive perverted thinking processes or other purely endogenous
sources. The social navigation hypothesis calls instead for a penetrating analysis of the
depressive’s talents and dreams, identification of relevant social constraints (especially
those with a relatively diffuse non-point source within the social network of the depressive),
and practical social problem-solving therapy designed to relax those constraints enough to allow
the depressive to move forward with their life under an improved set of social contracts.
- Bargaining theory: This theory is similar to the honest signaling, niche change, and social
navigation theory. It basically adds one additional element to honest signaling theory. The
fitness of social partners is generally correlated. When a wife suffers depression and reduces
her investment in offspring, for example, the husband's fitness is also put at risk. Thus, not
only do the symptoms of major depression serve as costly and therefore honest signals of need,
they also compel social partners to respond to that need in order to prevent their own fitness
from being reduced. See, e.g., Hagen 1999, Hagen 2003.
- Darwinian Psychiatry: This "failure of model-integration" theory is focused on behavioral
systems (i.e., reproduction, survival, kin-investment, reciprocation), in which individuals
have a marked functional consequences due to both ultimate and proximate condition-producing
causes (plural). Using the 15% Principle, it distinguishes between (and incorporates)
physiological, phenotypical, trait variational, dysfunctional algorithms, dysfunctional
automatic, and adverse environmental systems, wherein individuals act adaptively, albeit
suboptimally, even with dysregulation, and is then assigned a ratio to each of the manifold
contributing factors, creating a profile of both proximate and ultimate causal factors for
which depressive features are locked-in adaptations. Joining "evolved capacities" and "adequate
functioning," it argues that many features of clinical depression are adaptive, albeit
suboptimally and dysfunctionally. Using "homeostasis" as a benchmark of healthy life-strategies,
depressions are regarded as minimally conservative of individual energies in which the failure to
adapt, or precipitating incidents, rapid resolutions, creative capacities, physiological
responses, trait variation, interpersonal conflicts, maturational disruptions, and suboptimal
information-processing trigger depressive responses in individuals in order to achieve more
modest goals within each of the four major behavioral systems. (Reactive depressions, or
"response-to-loss" models, are a separate adaptive responses to functioning, usually transient
and self-correcting.) The depressive's cost-benefit analyses are also incorporated in the final
assessment, and then psychiatric treatment strategies are designed to treat all the multi-causal
factors together as a holistic phenomenon through empirically-validated modalities.
Treatment
Treatment of depression varies broadly and differs from one individual to another. Various types and combinations of
treatments may have to be tried, but without hope in a complete solution to the problem. There are two primary modes
of treatment, typically used in conjunction: medication and psychotherapy. A third treatment, electroconvulsive therapy
(ECT), may be used when chemical treatment fails.
Alternative treatments used for depression include exercise and the use of vitamins, herbs, or other nutritional
supplements.
The effectiveness of treatment often depends on factors such as the amount of optimism and hope the sufferer is able
to maintain, the control s/he has over stressors, the severity of symptoms, the amount of time the sufferer has been
depressed, the results of previous treatments, and the degree of support of family, friends, and significant others.
Although treatment is generally effective, in some cases the condition does not respond. Treatment-resistant depression
warrants a full assessment, which may lead to the addition of psychotherapy, higher medication dosages, changes of
medication or combination therapy, a trial of ECT/electroshock, or even a change in the diagnosis, with subsequent
treatment changes. Although this process helps many, some people's symptoms continue unabated.
In emergencies, psychiatric hospitalization is used simply to keep suicidal people safe until they cease to be dangers
to themselves. Another treatment program is partial hospitalization, in which the patient sleeps at home but spends
the day, either five or seven days a week, in a psychiatric hospital setting in intense treatment. This treatment usually
involves group therapy, individual therapy, psychopharmacology, and academics (in child and adolescent programs).
Medication
Medication that relieves the symptoms of depression has been available for several decades. These drugs are listed in
order of historical development. Typical first-line therapy for depression is the use of an selective serotonin
reuptake inhibitor, such as citalopram (Celexa), fluoxetine (Prozac), paroxetine (Paxil), and sertraline (Zoloft).
Under some circumstances, medication and psychotherapy may be more effective than either treatment separately.
Monoamine oxidase inhibitors (MAOIs) such as Nardil may be used if other antidepressant medications are ineffective.
Because there are potentially fatal interactions between this class of medication and certain foods and drugs, they
are rarely prescribed anymore. MAOI's are used to block the enzyme monoamine oxidase which breaks down neurotransmitters
such as serotonin and norepinephrine (noradrenaline). MAOI's are as effective as tricyclics, if not slightly more
effective. A new MAOI has recently been introduced. Moclobemide (Manerix), known as a reversible inhibitor of monoamine
oxidase A (RIMA), follows a very specific chemical pathway and does not require a special diet.
Tricyclic antidepressants are the oldest and include such medications as amitriptyline and desipramine. Tricyclics
block the reuptake of certain neurotransmitters such as norepinephrine (noradrenaline) and serotonin. They are used
less commonly now because of their side effects, which include increased heart rate, drowsiness, dry mouth,constipation,
urinary retention, blurred vision,dizziness, confusion, and
sexual dysfunction. Most importantly, they have a high
potential to be lethal in moderate overdose. However, tricyclic antidepressants are still used because of their high
potency, especially in severe cases of clinical depression.
Selective serotonin reuptake inhibitors (SSRIs) are a family of antidepressant considered to be the current standard
of drug treatment. It is thought that one cause of depression is an inadequate amount of serotonin, a chemical used
in the brain to transmit signals between neurons. SSRIs are said to work by preventing the reabsorption of serotonin
by the nerve cell, thus maintaining the levels the brain needs to function effectively, although two researchers
recently demonstrated that the advertised connection between seratonin deficiency and symptoms of depression is a
marketing technique rather than a scientific portrayal of how the drugs actually work. Recent research indicates that
these drugs may interact with transcription factors known as "clock genes," which may be important for the addictive
properties of drugs of abuse and possibly in
obesity.
This family of drugs includes fluoxetine (Prozac), paroxetine (Paxil), escitalopram (Lexapro), citalopram (Celexa),
and sertraline (Zoloft). These antidepressants typically have fewer adverse side effects than the tricyclics or the
MAOIs, although such effects as drowsiness, dry mouth, nervousness,
anxiety,
insomnia, decreased appetite, and decreased
ability to
function sexually may occur. Some side effects may decrease as a person adjusts to the drug, but other side
effects may be persistent.
Norepinephrine (noradrenaline) reuptake inhibitors (NRIs) such as reboxetine (Edronax) act via norepinephrine (also
known as noradrenaline). NRIs are thought to have a positive effect on concentration and motivation in particular.
Norepinephrine-dopamine reuptake inhibitors such as bupropion (Wellbutrin, Zyban) inhibit the neuronal reuptake of
dopamine and norepinephrine (noradrenaline).
Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine (Effexor) and duloxetine (Cymbalta) are a
newer form of antidepressant that works on both noradrenaline and serotonin. They typically have similar side effects
to the SSRIs, although there may be a withdrawal syndrome on discontinuation that may necessitate dosage tapering.
Noradrenergic and specific serotonergic antidepressants (NASSAs) form a newer class of antidepressants which purportedly
work to increase norepinephrine (noradrenaline) and serotonin neurotransmission by blocking presynaptic alpha-2 adrenergic
receptors while at the same time minimizing serotonin related side-effects by blocking certain serotonin receptors.
The only example of this class in clinical use is mirtazapine (Avanza, Zispin, Remeron).
Dietary Supplements
5-HTP supplements are claimed to provide more raw material to the body's natural serotonin production process. There
is a reasonable indication that 5-HTP may not be effective for those who haven't already responded well to an SSRI
because of their similar function: SSRIs allow the brain to use its serotonin more effectively, while 5-HTP induces
production of more serotonin.
S-adenosyl methionine (SAM-e) is a derivative of the amino acid methionine that is found throughout the human body,
where it acts as a methyl donor and participates in other biochemical reactions. It is available as a prescription
antidepressant in Europe and an over-the-counter dietary supplement in the United States. Clinical trials have shown
SAM-e to be as effective as standard antidepressant medication, with fewer side effects; however, some studies have
reported an increased incidence of mania resulting from SAM-e use compared to other antidepressants. Its mode of action
is unknown.
Omega-3 fatty acids (found naturally in oily fish, flax seeds, hemp seeds, walnuts, and canola oil) have also been found
to be effective when used as a dietary supplement (although only fish-based omega-3 fatty acids have shown antidepressant
efficacy.)
Dehydroepiandrosterone (DHEA), available as a supplement in the U.S., has been shown to be effective in small trials.
Magnesium supplementation has gathered some attention as a possible treatment for depression. Some case reports
demonstrate rapid recovery from major depression using magnesium treatment. "The possibility that magnesium deficiency
is the cause of most major depression and related mental health problems including IQ loss and
addiction is enormously
important to public health and is recommended for immediate further study."
St John's Wort (Hypericum perforatum) Traditionally used by 'wise women' and midwives for hundreds of years, to 'chase
away the devil' of melancholia and
anxiety. It is a mood-enhancing herbal substance which acts like an antidepressant
and increases the availability of serotonin, norepinephrine and dopamine at the neuron synapses. Also popular for
treating
insomnia, mood swings, fatigue, PMS and menopause. Except under medical supervision, St. John's Wort should
not be used with SSRIs or MAOIs due to the risk of serotonin syndrome.
Ginkgo Biloba Effective natural antidepressant said to stabilise cell membranes, inhibiting lipid breakdown and aiding
cell use of oxygen and glucose - so subsequently a mental and vascular stimulant that improves neurotransmitter
production. Also popular for treating mental concentration (such as for
Alzheimer's Disease and stroke patients).
Siberian Ginseng (Eleutherococcus senticosus) Although not a true panax ginseng it is a mood enhancement supplement
against stress. Also popular for treating depression,
insomnia, moodiness, fatigue, poor memory, lack of focus, mental
tension and endurance.
Zinc has had an antidepressant effect in an experiment.
Biotin: a deficiency has caused a severe depression. The patient's symptoms improved after the deficiency was
corrected.
Vitamin B-12: Symptoms of a vitamin B-12 deficiency can include depression and other psychiatric disorders.
The amino acids phenylalanine and tyrosine have also a favorable effect on easy forms of depression. They enhance the
neurotransmitters dopamine and noradrenalin.
Both kava and valerian root are said to contain naturally occurring properties which help to promote a natural cure
for depression.
Cannabis has also been shown to reduce the symptoms of depression.
Tryptophan For some time, tryptophan was available in health food stores as a dietary supplement. Since 2002,
L-Tryptophan has been sold again in its original form. Many people found tryptophan to be a safe and reasonably
effective sleep aid, probably due to its ability to increase brain levels of serotonin (a calming neurotransmitter
when present in moderate levels) and/or melatonin (a sleep-inducing hormone secreted by the pineal gland in response
to darkness or low light levels). A biological path or precursor to 5-HTP.
Augmentor Drugs
Some antidepressants have been found to work more effectively in some patients when used in combination with another
drug. Such "augmentor" drugs include tryptophan (Tryptan) and buspirone (Buspar).
Tranquillizers and sedatives, typically the benzodiazepines, may be prescribed to ease
anxiety and promote sleep. Because of
their high potential for fostering dependence, these medications are intended only for short-term or occasional use. Medications
often are used not for their primary function but to exploit what are normally side effects. Quetiapine fumarate (Seroquel) is
designed primarily to treat
schizophrenia and
bipolar disorder, but a frequently reported side-effect is somnolence. Therefore,
this drug can be used in place of an antianxiety agent such as clonazepam (Klonopin, Rivotril).
Antipsychotics such as risperidone (Risperdal), olanzapine (Zyprexa), and Quetiapine (Seroquel) are prescribed as mood
stabilizers and are also effective in treating
anxiety. Their use as mood stabilizers is a recent phenomenon and is controversial
with some patients. Antipsychotics (typical or atypical) may also be prescribed in an attempt to augment an antidepressant, to
make antidepressant blood concentration higher, or to relieve psychotic or paranoid symptoms often accompanying clinical
depression. However, they may have serious side effects, particularly at high dosages, which may include blurred vision,
muscle spasms, restlessness, tardive dyskinesia, and weight gain.
Antidepressants by their nature behave similarly to psychostimulants. Antianxiety medications by their nature are
depressants. Close medical supervision is critical to proper treatment if a patient presents with both illnesses
because the medications tend to work against each other.
Psycho-stimulants are sometimes added to an antidepressant regimen if the patient suffers from anhedonia, hypersomnia
and/or excessive eating as well as low motivation. These symptoms which are common in atypical depression can be quickly
resolved with the addition of low to moderate dosages of amphetamine or methylphenidate (brand names Adderall and
Ritalin, respectively)as these chemicals enhance motivation and social behavior, as well as suppress appetite and
sleep. These chemicals are also known to restore sex drive. Extreme caution must be used however with certain
populations. Stimulants are known to trigger manic episodes in people suffering from
bipolar disorder. They are also
easily abused as they are effective substitutes for Methamphetamine when used recreationaly. Close supervision of those
with substance abuse disorders is urged. Emotionally labile patients should avoid stimulants, as they exacerbate mood
shifting.
Lithium remains the standard treatment for
bipolar disorder and is often used in conjunction with other medications,
depending on whether mania or depression is being treated. Lithium's potential side effects include thirst, tremors,
light-headedness, and nausea or diarrhea. Some of the anticonvulsants, such as carbamazepine (Tegretol), sodium
valproate (Epilim), and lamotrigine (Lamictal), are also used as mood stabilizers, particularly in
bipolar disorder.
Psychotherapy
In psychotherapy, or counseling, one receives assistance in understanding and resolving habits or problems that may
be contributing to or the cause of the depression. This may be done individually or with a group and is conducted by
mental health professionals such as psychiatrists, psychologists, clinical social workers, or psychiatric nurses.
Effective psychotherapy may result in different habitual thinking and action which leads to a lower relapse rate than
antidepressant drugs alone. Medication, however, may yield quicker results and be strongly indicated in a crisis.
Medication and psychotherapy are generally complementary, and both may be used at the same time.
It is important to ask about potential therapists' training and approach; a very close bond often forms between
practitioner and client, and it is important that the client feel understood by the clinician. Moreover, some approaches
have been convincingly demonstrated to be much more effective in treating depression.
Counselors can help a person make changes in thinking patterns, deal with relationship problems, detect and deal with
relapses, and understand the factors that contribute to depression.
There are many counseling approaches, but all are aimed at improving one's personal and interpersonal functioning.
Cognitive behavioral therapy has been demonstrated in carefully controlled studies to be among the foremost of the
recent wave of methods which achieve more rapid and lasting results than traditional "talk therapy" analysis. Cognitive
therapy, often combined with behavioral therapy, focuses on how people think about themselves and their relationships.
It helps depressed people learn to replace negative depressive thoughts with realistic ones, as well as develop more
effective coping behaviors and skills. Therapy can be used to help a person develop or improve interpersonal skills in
order to allow him or her to communicate more effectively and reduce stress. Interpersonal psychotherapy focuses on the
social and interpersonal triggers that cause their depression. Narrative therapy gives attention to each person's
"dominant story" by means of therapeutic conversations, which also may involve exploring unhelpful ideas and how they
came to prominence. Possible social and cultural influences may be explored if the client deems it helpful. Behavioral
therapy is based on the assumption that behaviors are learned. This type of therapy attempts to teach people more
healthful types of behaviors. Supportive therapy encourages people to discuss their problems and provides them with
emotional support. The focus is on sharing information, ideas, and strategies for coping with daily life. Family therapy
helps people live together more harmoniously and undo patterns of destructive behavior.
Transcranial Magnetic Stimulation
Repetitive transcranial magnetic stimulation (rTMS) is under study as a possible treatment for depression. Initially
designed as a tool for physiological studies of the brain, this technique shows promise as a means of alleviating
depression. In this therapy, a powerful magnetic field is used to stimulate the left prefrontal cortex, an area of
the brain that typically shows abnormal activity in depressed people.
Recent work in Poland suggested that weak, variable magnetic fields may offer relief from depression in those who have
not responded to medication. However, some of the existing work has been questioned, with claims that the effect is not
as significant once environmental conditions are controlled.
Vagus Nerve Stimulation
Vagus nerve stimulation therapy is a treatment used since 1997 to control seizures in epileptic patients and has
recently been approved for treating resistant cases of treatment-resistant depression (TRD). The VNS Therapy device
is implanted in a patient's chest with wires that connect it to the vagus nerve, which it stimulates to reach a region
of the brain associated with moods. The device delivers controlled electrical currents to the vagus nerve at regular
intervals.
Electroconvulsive Therapy
Electroconvulsive therapy (ECT), also known as electroshock or electroshock treatment, uses short bursts of a controlled
current of electricity (typically fixed at 0.9 ampere) into the brain to induce a brief, artificial seizure while the
patient is under general anesthesia.
ECT has acquired a fearsome reputation, in part from its use as a tool of repression in the former USSR and mind control
in USA and its barbaric fictional depiction in films such as One Flew Over the Cuckoo's Nest and Requiem for a Dream,
but remains a common treatment where other means of treatment have failed or where the use of drugs is unacceptable
(e.g. in the case of pregnant patients). Also, in contrast to direct electroshock of years ago, most countries now
allow ECT to be administered only under anaesthesia. In a typical regimen of treatment, a patient receives three
treatments per week over three or four weeks. Repeat sessions may be needed. Short-term memory loss, disorientation,
and headache are very common side effects. In some cases, permanent memory loss has occurred, but detailed
neuropsychological testing in clinical studies has not been able to prove permanent effects on memory. ECT offers the
benefit of a very fast response; however, this response has been shown not to last unless maintenance electroshock or
maintenance medication is used. Whereas antidepressants usually take around a month to take effect, the results of ECT
have been shown to be much faster. For this reason, it is the treatment of choice in emergencies (e.g., in catatonic
depression in which the patient has ceased oral intake of fluid or nutrients).
There remains much controversy over electroshock. Advocacy groups and scientific critics, such as Dr Peter Breggin,
call for restrictions on its use or complete abolishment. Like all forms of psychiatric treatment, electroshock can
be given without a patient's consent, but this is subject to legal conditions dependent on the jurisdiction. In Oregon
patient consent is necessary by statute. Treatment with ECT has been used as a threat by psychiatric ward staffers
against unruly patients.
Other Methods of Treatment
Light Therapy
Bright light (both sunlight and artificial light) is shown to be effective in seasonal affective disorder, and
sometimes may be effective in other types of depression, especially atypical depression or depression with "seasonal
phenotype" (overeating, oversleeping, weight gain, apathy).
Exercise
It is widely believed that physical activity and exercise help depressed patients and promote quicker and better
relief from depression. They are also thought to help antidepressants and psychotherapy work better and faster. It
can be difficult to find the motivation to exercise if the depression is severe, but sufferers should be encouraged
to take part in some form of regularly scheduled physical activity. A workout need not be strenuous; many find walking,
for example, to be of great help. Exercise produces higher levels of chemicals in the brain, notably dopamine, serotonin,
and norepinephrine. In general this leads to improvements in mood, which is effective in countering depression.
Meditation
Meditation is increasingly seen as a useful treatment for some cases of depression. The current professional opinion on
meditation is that it represents at least a complementary method of treating depression, a view that has been endorsed
by the Mayo Clinic. Since the late 1990s, much research has been carried out to determine how meditation affects
the brain (see the main article on meditation). Although the effects on the mind are complex, they are often quite
positive, encouraging a calm, reflective, and rational state of mind that can be of great help against depression.
Although many religions include meditative practice, it is not necessary to be a member of any faith to meditate.
Some people choose to supplement their conventional treatments for depression with techniques such as Aromatherapy,
Hypnotherapy, Acupuncture and Crystal Therapy.
Deep Brain Stimulation
Though still experimental, a new form of treatment called deep brain stimulation offers some hope in the relief of
treatment resistant clinical depression. Published in the journal Neuron (2005), Helen Mayberg described the implanting
of electrodes in a region of the brain known as Area 25 (Neuron). The electrodes act in an inhibitory fashion, on an
otherwise overactive region of the brain. Further research is required before it becomes available as a method of
treatment, but it offers hope for those suffering from treatment resistant depression.
Archaic Methods
Insulin shock therapy is an old and largely abandoned treatment of severe depressions, psychoses, catatonic states,
and other mental disorders. It consists of induction of hypoglycemic coma by intravenous infusion of insulin. The
treatment is potentially unsafe and is lethal in about 1% of patients, even with proper monitoring. In contrast, ECT
is considered to be very safe.
Nevertheless, insulin shock therapy is still officially used in Russia and some other countries and can be administered
to a very treatment-resistant patient with written consent in many Western countries.
Atropinic shock therapy, also known as atropinic coma therapy, is an old and rarely used method. It consists of
induction of atropinic coma by rapid intravenous infusion of atropine.
Atropinic shock treatment is considered safe, but it entails prolonged coma (4-5 hours), with careful monitoring
and preparation, and it has many unpleasant side effects, such as blurred vision. It can be used with written consent
in Western countries in very treatment-resistant patients and is still officially used in Russia and some other
countries.
Trepanation, drilling a hole through the skull to "release" the negative spirits or increase brain bloodflow, was
used in some ancient cultures.
Self Medication
Some people with clinical depression may attempt to dull their feelings of despair by consuming alcohol, tobacco,
or illicit drugs. Some people with depression may resort to alcohol, heavy tobacco smoking, cocaine, opiates or
amphetamines for their mood-altering effects. Using drugs or alcohol should not be thought of as self-medication.
It is an outdated idea, and it presumes that these drugs have some small medicinal value in depression, and that
people choose them consciously for that reason. Both of these premises are false. An antidepressant medication should
change the progression of the disease, not merely mask symptoms. People become dependent on drugs and alcohol because
of a genetic predisposition, not a conscious choice to use them for some specific purpose.
"Comfort foods" are also used by some. Some foods like chocolate contain psychoactive substances.
Adverse Reactions
Aspartame was associated with a significant difference in number and severity of symptoms for patients with a history
of depression in an experiment. However, the main findings of this 1993 study have not been replicated since, and its
methodology has been criticized on the basis that unrelated symptoms were aggregated artificially, thereby boosting the
statistical difference between the aspartame and the placebo conditions.
Relapse
Relapse is more likely if treatment has not resulted in full remission of symptoms. In fact, current guidelines for
antidepressant use recommend 4 to 6 months of continuing treatment after symptom resolution to prevent relapse.
Combined evidence from many randomized controlled trials indicates that continuing antidepressant medications after
recovery substantially reduces (halves) the chances of relapse. This preventive effect probably lasts for at least
the first 36 months of use.
Anecdotal evidence suggests that chronic disease is accompanied by relapses after prolonged treatment with
antidepressants (tachyphylaxis). Psychiatric texts suggest that physicians respond to relapses by increasing dosage,
complementing the medication with a different class, or changing the medication class entirely. The reason for relapse
in these cases is as poorly understood as the change in brain physiology induced by the medications themselves.
Possible reasons may include aging of the brain or worsening of the condition. Most SSRI psychiatric medications were
developed for short-term use (a year or less) but are widely prescribed for indefinite periods.
Social Attitudes Towards Depression
Employment
Some employers are reluctant to consider hiring people with a history of depression, but discrimination on this
basis may be illegal in the United States. U.S. military standards do not allow more than six months of treatment
for depression before someone becomes ineligible, though a waiver is possible in some circumstances.
Mental Health Stigma
Because mental illness does not have the visible symptoms most non-mental disorders do, treatment has often been
considered less important or deserved than for physical illness. Many insurance plans do not cover mental health
services to the same degree as other illnesses. Many jurisdictions are introducing legislation to provide parity in
coverage between mental and non-mental illness.
(adapted from Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Clinical_depression)
Authors: Tull MT, Gratz KL.
Center for Addictions, Personality, and Emotion Research, University of Maryland, United States; Department of Psychology, University of Maryland, College Park, MD 20742, United States.
This study examined the role of experiential avoidance and difficulties engaging in goal-directed behavior when distressed
in the relationship between
sensitivity (AS) and depressive symptom severity. A sample of 391 undergraduate students
completed a series of questionnaires assessing the constructs of interest. Results provided support for a model where
experiential avoidance and difficulties engaging in goal-directed behavior mediate the relationship between the AS
dimensions of fear of cognitive dyscontrol and fear of publicly observable
reactions and depressive symptom
severity. The ability of this model to distinguish participants (N=53) reporting clinical levels of depression from those
without (N=53) was then examined. The model was found to reliably distinguish between participants with and without clinical
levels of depression. However, only experiential avoidance was a significant mediator. Implications for research on the
role of AS in depression vulnerability and treatment are discussed.
Journal: J Anxiety Disord. 2007 Mar 14;
Authors: Papakostas GI, Fava M.
Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WAC 812, Boston, MA 02114, USA.
OBJECTIVE: To compare response rates among patients with major depressive disorder (MDD) treated with either a serotonin-2
(5HT2-) receptor antagonist or a selective serotonin reuptake inhibitor (SSRI). METHODS: Medline and PubMed were searched
for double-blind, randomized clinical trials comparing either trazodone or nefazodone with an SSRI for the treatment of MDD.
Data from 9 reports involving a total 988 patients were identified and combined using a random-effects model. RESULTS:
Patients randomized to treatment with a 5HT2 antagonist were as likely to experience clinical response as patients
randomized to treatment with an SSRI (RR=1.002, 95% CI: 0.85-1.17, P=0.978). Pooled response rates for trazodone/nefazodone
and the SSRIs were 61.1% and 61.7%, respectively. There was also no difference in overall discontinuation rates (P=0.334),
discontinuation due to adverse events (P=0.676), or discontinuation due to inefficacy (P=0.289) between the two groups.
CONCLUSIONS: These results suggest that the 5HT2-receptor antagonists trazodone and nefazodone and the SSRIs do not differ
with respect to their overall efficacy and tolerability in the treatment of MDD. Although the sample size was relatively
large and conveyed sufficient statistical power to test for differences in the overall sample, depression is a heterogeneous
condition and differences may exist between treatments in particular subgroups of patients.
Journal: Eur Psychiatry. 2007 Apr 4;
Authors: Johnson S, Tran T.
University of Miami.
Randomized controlled trials of psychological treatment, principally cognitive therapy, for
have yielded
inconsistent results. Given the status of this evidentiary base, we provide a more fine-grained analysis of the cognitive
profiles associated with
to inform clinical practice. In this practice-friendly review, we consider
evidence that both negative and positive cognitive styles are related to bipolar disorder. Cross-sectional and prospective
evidence suggest that negative cognitive styles are related to depression within
, but there also is
evidence that bipolar disorder is related to an elevated focus on goals as well as to increases in confidence during manic
states. With such findings as backdrop, we consider the outcomes of psychological treatments for
and
advance several suggestions for clinical practice. (c) 2007 Wiley Periodicals, Inc. J Clin Psychol: In Session 63: 425-432,
2007.
Journal: J Clin Psychol. 2007 Apr 6;63(5):425-432
Authors: Lung FW, Chen NC, Shu BC.
aDepartment of Psychiatry, Military Kaohsiung General Hospital bGraduate Institute of Behavioral Sciences, Kaohsiung Medical University cDepartment of Psychiatry, National Defense Medical University dCNS Marketing, Janssen-Cilag eDepartment of Psychiatry fInstitute of Allied Health Sciences and School of Nursing, National Cheng-Kung University, Taiwan.
CONTEXT: Shortened telomeric length has been associated with aging and monoamine oxidase A gene activity. The pathways of
genetic activity and mental disorder in shortening telomeric length, however, remain unclear. OBJECTIVE: The purpose of this
study was to explore the possible pathways of the monoamine oxidase A promoter, ApoE polymorphisms and telomeric length in
major depressive disorder. METHODS: This study enrolled 253 unrelated patients with major depression in southern Taiwan, and
was carried out between March 2001 and September 2004. In addition, 411 controls were randomly selected from the general
population in southern Taiwan. RESULTS: Hierarchical regression showed that the influence of the monoamine oxidase A
promoter and ApoE2 polymorphisms was not statistically significant to telomeric length, when additionally adjusting for
major depressive disorder. A final robust structural equation model showed that aging and major depressive disorder both
have a statistically significant shortening effect on telomeric length. Moreover, sex, the Apoϵ2 allele, and the
monoamine oxidase A promoter polymorphism have indirect effects on telomeric length. CONCLUSION: Major depressive disorder
is a mediating factor between the monoamine oxidase A promoter polymorphism and telomeric length.
Journal: Psychiatr Genet. 2007 Jun;17(3):195-199.
Authors: Paleacu D, Shutzman A, Giladi N, Herman T, Simon ES, Hausdorff JM.
*Neurology Service and Memory Clinic, Abarbanel Mental Health Center, Bat-Yam, Israel; daggerDepartments of Neurology and Physical Therapy, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; double daggerMovement Disorders Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; section signDepartment of Clinical Science, NeuroTrax Corp, New York, NY; and the parallelDivision on Aging, Harvard Medical School, Boston, MA.
OBJECTIVE: To investigate the relationship among affective status, cognitive function, and gait in depressed patients and
to evaluate the effects of treatment of depression on gait and cognitive function. METHODS: Nineteen patients recently
diagnosed with clinical depression (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) were
recruited from a psychiatric outpatient clinic. Evaluation included the Hamilton Depression Rating Scale (HAM-D), the
Mini-Mental State Examination, a computerized neuropsychological battery (Mindstreams, NeuroTrax Corp, New York, NY), and
Barthel's Index of Instrumental Activities of Daily Living. Temporal parameters of gait were quantified using a stopwatch
and force-sensitive insoles. All assessments were performed at baseline and after approximately 10 weeks of treatment with
antidepressants. RESULTS: The patients' mean age was 68.6 +/- 9.1 years (15 women). Therapy significantly (P < 0.001)
improved the affective state (HAM-D scores). There were small but significant improvements in gait speed (P = 0.033),
stride time variability (P = 0.036), and gait asymmetry (P = 0.038). With the exception of the hand-eye coordination index,
all tested cognitive domains also improved significantly. Baseline depression scores correlated with changes in depression:
patients with higher HAM-D scores at baseline had more significant improvement in their affect (P < 0.001). Changes in
HAM-D were not significantly correlated with changes in gait or changes on computerized tests of cognitive function
(P > 0.10). CONCLUSIONS: Depressive symptoms are associated with gait and cognitive impairment. Moreover, the present
results suggest that these domains improve in response to antidepressant medication.
Journal: Clin Neuropharmacol. 2007 March/April;30(2):63-71.
Authors: Weinstein AA, Deuster PA, Kop WJ.
1Uniformed Services University of the Health Sciences, Bethesda, MD; and 2University of Maryland, Baltimore, MD.
INTRODUCTION/PURPOSE: Negative mood symptoms occur frequently in sedentary populations, but individual vulnerability
factors for developing these complaints have not been systematically evaluated. This investigation examined whether the
autonomic nervous system (ANS) serves a role in the development of negative mood after controlled exercise withdrawal.
METHODS: Forty participants (mean age of 31.3 +/- 7.5 yr, 55% women) who exercised regularly (>/= 30 min of continuous
aerobic exercise at least three times a week during the past 6 months) were randomized either to withdrawal from regular
aerobic exercise (N = 20) or to continue regular aerobic exercise (N = 20) for 2 wk. Measurements were taken before exercise
withdrawal and at 2-wk follow-up. Various dimensions of negative mood were measured with the multidimensional fatigue
inventory, profile of mood states, and Beck depression inventory-II. ANS activity was assessed by heart rate variability
(HRV) analyses, examining low-frequency (0.04-0.15 Hz: lf) and high-frequency (hf) domains (0.15-0.40 Hz). The lf/hf ratio
was used as index of sympathovagal balance. Protocol adherence was documented by ambulatory activity monitoring. RESULTS:
Exercise withdrawal resulted in significantly higher negative mood scores at follow-up compared with control (P < 0.05).
Baseline lf/hf ratios correlated with the increases in symptoms (r > 0.4; P < 0.05) in the exercise-withdrawal
group independently of gender, age, weight, baseline fitness level, and baseline symptom status. The exercise-withdrawal
and control groups displayed no significant change in hf HRV, lf HRV, or lf/hf HRV during the 2 wk. CONCLUSION: Reduced
parasympathetic ANS activity as measured by HRV is predictive of the development of negative mood after deprivation of usual
exercise activities. No significant changes in HRV were observed during the 2-wk exercise deprivation period. These
findings are relevant to the understanding of mood changes in response to short-term exercise withdrawal, such as sports
injuries and recovery from medical procedures.
Journal: Med Sci Sports Exerc. 2007 Apr;39(4):735-41.
Authors: McIntyre RS, Konarski JZ, Soczynska JK, Kennedy SH.
MCINTYRE, KONARSKI, SOCZYNSKA, and KENNEDY: University of Toronto, Toronto, Ontario, Canada.
among residual depressive symptoms in
naturalistic primary care settings. METHODS: A post-hoc analysis of a database comprised of naturalistically treated
depressed patients across Canada was done. This bilingual (English and French), multi-center, randomized validation study
was conducted in 47 primary care settings in four provinces of Canada. Patients who met Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition, Text-Revision (DSM-IV-TR) criteria for a major depressive episode, in the context of a
major depressive disorder (N = 454) were enrolled. Eligible patients received open-label, flexible-dose antidepressant
treatment. The analysis reported here was limited to patients whose depression severity was evaluated using the Hamilton
Depression Rating Scale (HAMD-17) (n = 205). Patients completing 8 weeks of open-label antidepressant treatment (n = 157)
were considered evaluable. As a proxy for
, gastrointestinal distress, fatigue, hypochondriasis, and insight into illness) were summed to arrive at a
composite anxiety score, which was then used to calculate an anxiety ratio (with the composite anxiety score as the
numerator and the total HAMD-17 score as the denominator). RESULTS: The composite
ratio at baseline did not
correlate with the probability of remitting at endpoint (p = 0.534). After 8 weeks of antidepressant therapy, remitting
patients evinced a statistically significant decrease in
ratio (p = 0.041). Moreover, an inverse correlation was
noted between severity of anxious symptoms at endpoint and probability of remission (p = 0.026). The burden of anxiety,
presented as the
ratio, was higher in non-remitting patients at endpoint (p = 0.828). CONCLUSION: Residual
depressive symptoms represent ongoing illness activity in depression. Sharpening the focus of therapeutic interventions in
the clinical environment calls for tracking and managing residual
symptoms.
Journal: J Psychiatr Pract. 2007 Mar;13(2):125-8.
- Become a free member and get notified about studies in your area when they become available.
- Look over all of our current studies being conducted throughout the United States.